書誌情報
LBA-1. DREAMM-11: Safety and Tolerability of Belantamab Mafodotin Monotherapy in Japanese Patients with Relapsed/Refractory Multiple Myeloma
Crossman Timothy5, Kremer Brandon E. 6, Gupta Ira7, Kazutaka Sunami1, Shinsuke Iida2, Yuko Mishima3, Taku Fujii4, Hitomi Kato4, Takumi Terao4, Mari Matsubara4, Timothy Crossman5, Brandon E. Kremer6, Ira Gupta7
1Department of Hematology, National Hospital Organization Okayama Medical Center, 2Department of Hematology and Oncology, Nagoya City University Institute of Medical and Pharmaceutical Sciences, 3Department of Hematology Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, 4GlaxoSmithKline, 5Oncology Global Clinical Development, GlaxoSmithKline, 6Clinical Development, GlaxoSmithKline, Upper Providence, 7Clinical Oncology, GlaxoSmithKline, Upper Providence
International Journal of Myeloma 12(3): 114-114, 2022.
個人会員・法人会員の方（IDが5または10で始まる方）
- 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
